Cholinergic Receptor Activation by Pyridostigmine Restores Growth Hormone (GH) Responsiveness to GH Releasing Hormone Administration in Obese Subjects: Evidence for Hypothalamic Somatostatinergic Participation in the Blunted GH Release of Obesity*

1989 ◽  
Vol 68 (2) ◽  
pp. 290-293 ◽  
Author(s):  
FERNANDO CORDIDO ◽  
FELIPE F. CASANUEVA ◽  
CARLOS DIEGUEZ
Keyword(s):  
Growth Hormone ◽  
Cholinergic Receptor ◽  
Receptor Activation ◽  
Releasing Hormone ◽  
Hormone Administration ◽  
Obese Subjects

Effects of Growth Hormone Releasing Hormone Administration in Healthy Aging Men

1995 ◽  
pp. 257-265
Author(s):  
M. R. Blackman ◽  
J. Vittone ◽  
E. Corpas ◽  
J. Busby-Whitehead ◽  
T. Stevens ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Healthy Aging ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Hormone Administration ◽  
Aging Men

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects

1990 ◽  
Vol 122 (3) ◽  
pp. 385-390 ◽  
Author(s):  
R. C. Castro ◽  
J. G. H. Vieira ◽  
A. R. Chacra ◽  
G. M. Besser ◽  
A. B. Grossman ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Acetylcholinesterase Inhibitor ◽  
Random Order ◽  
Normal Subjects ◽  
Obese Patients ◽  
Releasing Hormone ◽  
Gh Secretion ◽  
Obese Subjects ◽  
Higher Doses ◽  
Hormone Responsiveness

Abstract Obese patients are characterised by several neuroendocrine abnormalities, including characteristically a decrease in growth hormone responsiveness to GH-releasing hormone. In normal subjects, the GH response to GHRH is enhanced by the acetylcholinesterase inhibitor, pyridostigmine. We have studied the effect of this drug on GH secretion in gross obesity. Twelve obese patients were studied (mean weight 156% of ideal) and compared with a group of 8 normal volunteers. Each subject was initially studied on two occasions, in random order, with GHRH (1–29) NH2 100 μg iv alone and following pretreatment with pyridostigmine 120 mg orally one hour prior to GHRH. In obese patients, the GH response to GHRH was significantly blunted when compared to controls (GH peak: 20 ± 4 vs 44 ± 16 μg/l; mean ± sem). After pyridostigmine, the response to GHRH was enhanced in the obese subjects, but remained significantly reduced compared to non-obese subjects treated with GHRH and pyridostigmine (GH peak: 30 ± 5 vs 77 ± 20 μg/l, respectively). In 6 subjects, higher doses of GHRH or pyridostigmine did not further increase GH responsiveness in obese patients. Our results suggest that obese patients have a disturbed cholinergic control of GH release, probably resulting from increased somatostatinergic tone. This disturbed regulation may be responsible, at least in part, for the blunted GH responses to provocative stimuli.

Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects

Metabolism ◽  
1999 ◽  
Vol 48 (9) ◽  
pp. 1152-1156 ◽  
Author(s):  
Roberto Lanzi ◽  
Livio Luzi ◽  
Andrea Caumo ◽  
Anna Claudia Andreotti ◽  
Marco Federico Manzoni ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Releasing Hormone ◽  
Insulin Levels ◽  
Obese Subjects
Sign in / Sign up

Export Citation Format

Share Document